2025-06-27 08:00
Annual Report for the finacial year 2024/2025 for Biovica International AB is published today on our website. See URL below Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: anders.rylander@biovica.com Anders Morén, CFOPhone: +46 73 125...
2025-06-26 08:00
Biovica today announced that the European Patent Office (EPO) has granted a new patent for the company’s biomarker technology in the field of immuno-oncology. The patent covers the use of TKa as a marker for predicting the efficacy of immune checkpoint...
2025-06-18 08:00
Positive development in the USA continues Biovica in brief – Treatment decisions with greater certainty Webcast:When: 18 June 2025, 3 PM to 4 PM CETWhere: register via: https://www.eventbrite.com/e/biovica-q4-earnings-call-2024-25-tickets-1392516366939Broadcast...
2025-06-11 09:47
Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) – along with an initial Work Order of ~800 kSEK – with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology...
2025-06-11 08:01
The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm...
2025-06-11 08:00
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...
2025-06-10 18:31
Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company’s recent commercial momentum and its long-term commitment to transparency and value creation for...
2025-06-10 08:00
Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two...
2025-05-23 08:00
Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June...
2025-05-19 08:30
Biovica, a leader in blood-based cancer monitoring, today announces the signing of a Master Service Agreement (MSA) with a US-based pharmaceutical and biotechnology company recognized as a Tier-1 player in oncology. A first work order has also been signed...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects